非酒精性脂肪性肝病相关肝细胞癌的发病机制及FXR和OCA的研究进展

Research progress of FXR and OCA,the pathogenesis of non-alcoholic fatty liver disease related hepatocellular carcinoma

非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)进展为肝细胞癌(hepatocellular carcinoma,HCC)的发病机制是相当复杂的,其中涉及多个方面,包括高胰岛素环境、细胞学机制、遗传多态性等。为预防NAFLD进展为HCC,干预和治疗NAFLD是必然的选择。法尼醇X受体(Farnesoid X receptor,FXR)的活化可以改善NAFLD的组织学特征。作为FXR激动剂奥贝胆酸(Obeticholic acid,OCA)又名6-乙基鹅去氧胆酸,是目前一种治疗NAFLD的新药物。本文就NAFLD相关HCC发病机制、FXR和OCA的研究进展作一概述。

The pathogenesis of non-alcoholic fatty liver disease （NAFLD） progress to hepatocellular carcinoma （HCC） is quite complex, which involves many aspects, including the high insulin environment, cytological mecha- nisms, genetic polymorphism and so on. In order to prevent the development of NAFLD as HCC, intervention and treat- ment of NAFLD are inevitable choice. The Farnesoid X receptor （FXR） activation can improve the histological features of NAFLD. As an FXR agonist, Obeticholic acid （ OCA, 6-ethylchenodeoxycholic acid） is a new drug for the treatment of NAFLD currently. In this article, the pathogenesis of NAFLD-related HCC, FXR and OCA research progress were introduced.